PMID- 28238190
OWN - NLM
STAT- MEDLINE
DCOM- 20170523
LR  - 20220310
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
VI  - 54
IP  - 5
DP  - 2017 May
TI  - Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with 
      type 2 diabetes mellitus: a double-blind randomized controlled trial.
PG  - 499-507
LID - 10.1007/s00592-017-0977-y [doi]
AB  - AIMS: The anti-inflammatory effects of the polyphenol resveratrol in patients 
      with type 2 diabetes mellitus (T2DM) are controversial. Its role on pentraxin 3 
      (PTX3) concentrations, a human acute phase protein, has never been evaluated. Our 
      aim was to determine whether a two-dosage resveratrol supplementation (500 and 
      40 mg/day) has an impact on PTX3 values in T2DM patients from a double-blind 
      randomized placebo-controlled trial. Variations in total antioxidant status (TAS) 
      were evaluated too. METHODS: A total of 192 T2DM patients were randomized to 
      receive resveratrol 500 mg/day (Resv 500 arm), resveratrol 40 mg/day (Resv 40 
      arm) or placebo for 6 months. At baseline and at the trial end, PTX3 and TAS 
      values were determined. RESULTS: A dose-dependent increase in PTX3 concentrations 
      of 4.7% (Resv 40 arm) and 26.3% (Resv 500 arm), and 8.0% reduction after placebo 
      were found. Adjusted mean differences of change versus placebo were 0.16 (95% CI 
      0.01-0.32) and 0.25 (0.09-0.42) in the Resv 40 and Resv 500 arms, respectively. 
      At subgroup analyses, lower diabetes duration, aspirin, alcohol use, younger age, 
      female gender, smoking (Resv 500 arm) and female gender and aspirin use (Resv 40 
      arm) were associated with higher PTX3 increments. A dose-dependent increment in 
      TAS values in the resveratrol arms (1.4 and 6.4% for Resv 40 and Resv 500, 
      respectively), and a reduction in placebo arm (-8.9%) were observed. Adjusted 
      mean differences of change were 28.5 (95% CI 10.1-46.8) and 44.8 (25.4-64.1) in 
      the Resv 40 and Resv 500 arms, respectively. CONCLUSION: Resveratrol 
      supplementation increased PTX3 and TAS levels in a dose-dependent manner in T2DM 
      patients. At present, potential clinical implications of these results remain 
      unclear. CLINICALTRIALS. GOV IDENTIFIER: NCT02244879.
FAU - Bo, S
AU  - Bo S
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy. simona.bo@unito.it.
FAU - Ponzo, V
AU  - Ponzo V
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Evangelista, A
AU  - Evangelista A
AD  - Unit of Clinical Epidemiology, CPO, "Citta della Salute e della Scienza" Hospital 
      of Turin, Turin, Italy.
FAU - Ciccone, G
AU  - Ciccone G
AD  - Unit of Clinical Epidemiology, CPO, "Citta della Salute e della Scienza" Hospital 
      of Turin, Turin, Italy.
FAU - Goitre, I
AU  - Goitre I
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Saba, F
AU  - Saba F
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Procopio, M
AU  - Procopio M
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Cassader, M
AU  - Cassader M
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
FAU - Gambino, R
AU  - Gambino R
AD  - Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126, 
      Turin, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT02244879
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170225
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 0 (Antioxidants)
RN  - 0 (Serum Amyloid P-Component)
RN  - 0 (Stilbenes)
RN  - 148591-49-5 (PTX3 protein)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antioxidants/*administration & dosage
MH  - C-Reactive Protein/*metabolism
MH  - Diabetes Mellitus, Type 2/*blood/diagnosis/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Resveratrol
MH  - Serum Amyloid P-Component/*metabolism
MH  - Stilbenes/*administration & dosage
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Pentraxin 3
OT  - Resveratrol
OT  - Total antioxidant status
OT  - Type 2 diabetes mellitus
EDAT- 2017/02/27 06:00
MHDA- 2017/05/24 06:00
CRDT- 2017/02/27 06:00
PHST- 2016/12/22 00:00 [received]
PHST- 2017/02/20 00:00 [accepted]
PHST- 2017/02/27 06:00 [pubmed]
PHST- 2017/05/24 06:00 [medline]
PHST- 2017/02/27 06:00 [entrez]
AID - 10.1007/s00592-017-0977-y [pii]
AID - 10.1007/s00592-017-0977-y [doi]
PST - ppublish
SO  - Acta Diabetol. 2017 May;54(5):499-507. doi: 10.1007/s00592-017-0977-y. Epub 2017 
      Feb 25.